HADI YASSINE

Dr. HADI YASSINE


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in Viruses
Verified
Journal Article
Open access
PDF file
MSMaria Smatti
Maria Smatti
FCFarhan Cyprian
Farhan Cyprian
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
ATAsmaa A. Al Thani
Asmaa A. Al Thani
RARuba O. Almishal
Ruba O. Almishal
HYHADI YASSINE
HADI YASSINE
For a long time, viruses have been shown to modify the clinical picture of several autoimmune diseases, including type 1 diabetes (T1D), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome (SS), herpetic stromal keratitis (HSK), celiac disease (CD), and multiple sclerosis (MS). Best examples of viral infections that have been proposed to modulate the induction and development of autoimmune diseases are the infections with enteric viruses such as Coxsackie B virus (CVB) and rotavirus, as well as influenza A viruses (IAV), and herpesviruses. Other viruses that have been studied in this context include, measles, mumps, and rubella. Epidemiological studies in humans and experimental studies in animal have shown that viral infections can induce or protect from autoimmunopathologies depending on several factors including genetic background, host-elicited immune responses, type of virus strain, viral load, and the onset time of infection. Still, data delineating the clear mechanistic interaction between the virus and the immune system to induce autoreactivity are scarce. Available data indicate that viral-induced autoimmunity can be activated through multiple mechanisms including molecular mimicry, epitope spreading, bystander activation, and immortalization of infected B cells. Contrarily, the protective effects can be achieved via regulatory immune responses which lead to the suppression of autoimmune phenomena. Therefore, a better understanding of the immune-related molecular processes in virus-induced autoimmunity is warranted. Here we provide an overview of the current understanding of viral-induced autoimmunity and the mechanisms that are associated with this phenomenon.

2 November 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PTPatrick Tang
Patrick Tang
MHMohammad R. Hasan
Mohammad R. Hasan
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha Benslimane
Fatiha Benslimane
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad

9 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
HYHADI YASSINE
HADI YASSINE
FBFatiha M. Benslimane
Fatiha M. Benslimane
HKHebah A. Al Khatib
Hebah A. Al Khatib
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad

26 May 2020 in Viruses
Verified
Journal Article
Open access
PDF file
NYNadin Younes
Nadin Younes
DADuaa W. Al-Sadeq
Duaa W. Al-Sadeq
HAHadeel Al-Jighefee
Hadeel Al-Jighefee
Salma YounesSalma Younes
Salma Younes
OAOla Al-Jamal
Ola Al-Jamal
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.

2 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHiam Chemaitelly
Hiam Chemaitelly
HAHoussein Ayoub
Houssein Ayoub
SASawsan AlMukdad
Sawsan AlMukdad
PCPeter Coyle
Peter Coyle
PTPatrick Tang
Patrick Tang
Laith Abu-RaddadLaith Abu-Raddad
Laith Abu-Raddad
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4–57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2–58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2–67.0%) and 43.7% (95% CI: 36.5–50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70–80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.

15 September 2020 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
AAAmani Audi
Amani Audi
MIMalak Al Ibrahim
Malak Al Ibrahim
MKMalak Kaddoura
Malak Kaddoura
GHGhina Hijazi
Ghina Hijazi
HYHADI YASSINE
HADI YASSINE
HZHassan Zaraket
Hassan Zaraket
Respiratory viruses, including coronaviruses, are known to have a high incidence of infection during winter, especially in temperate regions. Dry and cold conditions during winter are the major drivers for increased respiratory tract infections as they increase virus stability and transmission and weaken the host immune system. The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in China in December 2020 and swiftly spread across the globe causing substantial health and economic burdens. Several countries are battling with the second wave of the virus after a devastating first wave of spread, while some are still in the midst of their first wave. It remains unclear whether SARS-CoV-2 will eventually become seasonal or will continue to circulate year-round. In an attempt to address this question, we review the current knowledge regarding the seasonality of respiratory viruses including coronaviruses and the viral and host factors that govern their seasonal pattern. Moreover, we discuss the properties of SARS-CoV-2 and the potential impact of meteorological factors on its spread.